MicroRNAs (miRNAs) are small noncoding RNAs that post-transcriptionally inhibit gene expression. These small molecules are involved in several biological conditions such as inflammation, cell growth and proliferation, and regulation of energy metabolism. In the context of metabolic and cardiovascular diseases, miR-33 is of particular interest as it has been implicated in the regulation of lipid and glucose metabolism. This miRNA is located in introns harboured in the genes encoding sterol regulatory element-binding protein (SREBP)-1 and SREBP-2, which are key transcription factors involved in lipid biosynthesis and cholesterol efflux. This review outlines the role of miR-33 in a range of metabolic and cardiovascular pathologies, such as dyslipidaemia, nonalcoholic fatty liver disease (NAFLD), obesity, diabetes, atherosclerosis, and abdominal aortic aneurysm (AAA), and it provides discussion about the effectiveness of miR-33 deficiency as a possible therapeutic strategy to prevent the development of these diseases.
Leukocyte cell recruitment into the vascular subendothelium constitutes an early event in the atherogenic process. As the effect of the constitutive androstane receptor (CAR) on leukocyte recruitment and endothelial dysfunction is poorly understood, this study investigated whether the role of CAR activation can affect this response and the underlying mechanisms involved. Under physiological flow conditions, TNFα-induced endothelial adhesion of human leukocyte cells was concentration-dependently inhibited by preincubation of human umbilical arterial endothelial cells with the selective human CAR ligand CITCO. CAR agonism also prevented TNFα induced VCAM-1 expression, as well as MCP-1/CCL-2 and RANTES/CCL-5 release in endothelial cells. Suppression of CAR expression with a small interfering RNA abrogated the inhibitory effects of CITCO on these responses. Furthermore, CITCO increased interaction of CAR with Retinoid X Receptor (RXR) and reduced TNFα-induced p38-MAPK/NF-κB activation. In vivo, using intravital microscopy in the mouse cremasteric microcirculation treatment with the selective mouse CAR ligand TCPOBOP inhibited TNFα-induced leukocyte rolling flux, adhesion, and emigration and decreased VCAM-1 in endothelium. These results reveal that CAR agonists can inhibit the initial inflammatory response that precedes the atherogenic process by targeting different steps in the leukocyte recruitment cascade. Therefore, CAR agonists may constitute a new therapeutic tool in controlling cardiovascular disease-associated inflammatory processes.
Curcumin has been suggested to influence glucose homeostasis, but poor solubility and bioavailability limit understanding of its effects on β-cell function. Curcumin has also been reported to downregulate microRNA-33 (miR-33), a non-coding RNA involved in glucose homeostasis and insulin secretion. This study investigated the effects of a curcumin-based nanoformulation (Nano-CUR), designed to improve curcumin bioavailability, on miR-33 expression and islet function. Nano-CUR and a blank nanoformulation (Nano-BLK) were prepared using a modified thin-film hydration method. Mouse islets were incubated with vehicle-supplemented medium, unformulated curcumin (CUR), Nano-BLK or Nano-CUR for 24 hours. Cell viability was assessed by Trypan blue staining; insulin secretion and content were analysed via static incubation and radioimmunoassay; apoptosis was evaluated by measurement of caspase 3/7 activities; ATP production was quantified using a chemiluminescent assay; and miR-33 expression was determined by qPCR. Exposure of islets to vehicle, 5 µM CUR, 5 µM Nano-BLK, or 5 µM Nano-CUR did not compromise their viability, whereas 15 µM CUR and 15 µM Nano-BLK increased Trypan blue uptake. Noteably, 5 µM Nano-CUR, but not 5 μM CUR, enhanced basal, glucose- and carbachol-induced insulin secretion and increased insulin content, without altering basal or cytokine-induced β-cell apoptosis or ATP production. Furthermore, 5 μM Nano-CUR, but not 5 μM CUR, reduced islet miR-33a-5p expression. These findings indicate that Nano-CUR enhances β-cell function, likely via a glucose metabolism-independent mechanism involving miR-33 downregulation, highlighting its potential as a strategy to improve β-cell function.